Rimonabant is an inverse agonist at CB1 receptors that was briefly explored as an anti-obesity treatment but has since been withdrawn due to concerns about inducing depressive states in subjects. In animal models, rimonabant decreases food intake. Rimonabant also inhibits binding of antagonists to δ-opioid receptors in vitro. In retinal pigment epithelial cells, rimonabant prevents oxidative injury in a PI3K/Akt-dependent manner.
| Cas No. | 158681-13-1 |
|---|---|
| Purity | ≥98% |
| Formula Wt. | 500.25 |
| IUPAC Name | 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-piperidin-1-ylpyrazole-3-carboxamide;hydrochloride |
| Synonym | SR141716 |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | R3449 Info Sheet PDF |
|---|
Buckley JL, Rasmussen EB. Rimonabant's reductive effects on high densities of food reinforcement, but not palatability, in lean and obese Zucker rats. Psychopharmacology (Berl). 2014 May;231(10):2159-70. PMID: 24398820.
Zádor F, Kocsis D, Borsodi A, et al. Micromolar concentrations of rimonabant directly inhibits delta opioid receptor specific ligand binding and agonist-induced G-protein activity. Neurochem Int. 2014 Feb;67:14-22. PMID: 24508403.
Stuart SA, Butler P, Munafò MR, et al. A translational rodent assay of affective biases in depression and antidepressant therapy. Neuropsychopharmacology. 2013 Aug;38(9):1625-35. PMID: 23503126.
Wei Y, Wang X, Zhao F, et al. Cannabinoid receptor 1 blockade protects human retinal pigment epithelial cells from oxidative injury. Mol Vis. 2013;19:357-66. PMID: 23441106.
